In recent years, clinical drug trials targeting the inhibition of Aβ proteins or abnormal Tau proteins have failed to achieve the expected efficacy, casting a cloud over the development of anti-AD drugs (Castello et al., 2014; Mullard, 2021). Here, MAPT is linked to Alzheimer disease.